RxDoctor Payments Data

Lauri Shebesh

Nurse Practitioner · Sherman, TXNPI 1558870790

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Livanova USA, Inc. at 29.8% of the total. Reporting peaked in 2024 at $5,669 and has fallen 72.9% since, to $1,534 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,995in general payments, 2019–2025

Across 500 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$4K
  • Medtronic$2K
  • AbbVie$2K
  • Boston Scientific$1K
  • Abbott$1K
  • UCB, Inc.$682
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$6,15641%
  • Food & beverage$8,79359%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,995 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5039$200,227
IngrezzaValbenazine Tosylate23$192,818
ZeposiaOzanimod Hydrochloride14$125,740
QuliptaAtogepant56$72,154
RytaryCarbidopa/Levodopa76$71,568
NuplazidPimavanserin Tartrate14$62,217
UbrelvyUbrogepant29$41,431
AptiomEslicarbazepine Acetate13$34,981
Lamictal XrLamotrigine11$31,090
Nurtec OdtRimegepant Sulfate25$30,912
GlatopaGlatiramer Acetate13$28,302
RexultiBrexpiprazole15$23,820
OngentysOpicapone17$15,567
Aimovig AutoinjectorErenumab-Aooe18$14,259
XadagoSafinamide Mesylate12$12,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$339$208,38540 claims
AbbVieQulipta, Ubrelvy$1,821$113,58685 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$184$74,517103 claims
Acadia Pharmaceuticals IncNuplazid$64$62,21714 claims
PfizerNurtec Odt, Dilantin$505$32,74037 claims
Otsuka America Pharmaceutical, Inc.Rexulti$24$23,82015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →